Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Consolidated Net Income: 2021-2025

Historic Consolidated Net Income for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • Kiniksa Pharmaceuticals International's Consolidated Net Income rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Consolidated Net Income stood at $18.4 million for Q3 2025, which was up 3.38% from $17.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Consolidated Net Income ranged from a high of $224.1 million in Q3 2022 and a low of -$49.5 million during Q1 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Consolidated Net Income value was -$8.9 million (recorded in 2024), while the average stood at -$5.3 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Consolidated Net Income soared by 833.67% in 2022, and later slumped by 155.63% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Consolidated Net Income (Quarterly) stood at -$44.1 million in 2021, then surged by 300.84% to $88.5 million in 2022, then plummeted by 155.63% to -$49.2 million in 2023, then soared by 81.95% to -$8.9 million in 2024, then skyrocketed by 245.24% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $17.8 million for Q2 2025, and $8.5 million during Q1 2025.